Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial

IMPORTANCE: The GeparSixto trial provided evidence that the addition of neoadjuvant carboplatin to a regimen consisting of anthracycline, taxane, and bevacizumab increases pathological complete response (pCR) rates in patients with triple-negative breast cancer (TNBC). Whether BRCA1 and BRCA2 germli...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:JAMA Oncol
Main Authors: Hahnen, Eric, Lederer, Bianca, Hauke, Jan, Loibl, Sibylle, Kröber, Sandra, Schneeweiss, Andreas, Denkert, Carsten, Fasching, Peter A., Blohmer, Jens U., Jackisch, Christian, Paepke, Stefan, Gerber, Bernd, Kümmel, Sherko, Schem, Christian, Neidhardt, Guido, Huober, Jens, Rhiem, Kerstin, Costa, Serban, Altmüller, Janine, Hanusch, Claus, Thiele, Holger, Müller, Volkmar, Nürnberg, Peter, Karn, Thomas, Nekljudova, Valentina, Untch, Michael, von Minckwitz, Gunter, Schmutzler, Rita K.
Format: Artigo
Sprog:Inglês
Udgivet: American Medical Association 2017
Fag:
Original Investigation
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5710508/
https://ncbi.nlm.nih.gov/pubmed/28715532
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2017.1007
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker